Si Bone, Inc. SIBN
We take great care to ensure that the data presented and summarized in this overview for SI-BONE, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SIBN
View all-
Black Rock Inc. New York, NY3.85MShares$67 Million0.0% of portfolio
-
American Century Companies Inc Kansas City, MO2.84MShares$49.4 Million0.02% of portfolio
-
Brown Advisory Inc2.77MShares$48.3 Million0.06% of portfolio
-
Orbimed Advisors LLC San Diego, CA2.58MShares$44.9 Million1.3% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.49MShares$43.4 Million0.0% of portfolio
-
Champlain Investment Partners, LLC Burlington, VT2.11MShares$36.7 Million0.25% of portfolio
-
First Light Asset Management, LLC Edina, MN1.92MShares$33.4 Million3.39% of portfolio
-
Silvercrest Asset Management Group LLC New York, NY1.46MShares$25.5 Million0.15% of portfolio
-
Nuveen, LLC Charlotte, NC1.35MShares$23.6 Million0.01% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL1.26MShares$22 Million0.01% of portfolio
Latest Institutional Activity in SIBN
Top Purchases
Top Sells
About SIBN
SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
Insider Transactions at SIBN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 08
2026
|
Jeffrey W Dunn |
SELL
Open market or private sale
|
Indirect |
20,000
-19.98%
|
$420,000
$21.28 P/Share
|
|
Jan 02
2026
|
Anshul Maheshwari Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,229
-0.95%
|
$99,351
$19.64 P/Share
|
|
Jan 02
2026
|
Michael A Pisetsky SVP, Ops & Adm/Chief Legal Ofr |
SELL
Open market or private sale
|
Direct |
3,460
-0.5%
|
$65,740
$19.67 P/Share
|
|
Jan 02
2026
|
Anthony J Recupero President, Commercial Ops |
SELL
Open market or private sale
|
Direct |
3,677
-0.69%
|
$69,863
$19.63 P/Share
|
|
Dec 18
2025
|
Michael A Pisetsky SVP, Ops & Adm/Chief Legal Ofr |
SELL
Open market or private sale
|
Direct |
19,600
-7.79%
|
$392,000
$20.15 P/Share
|
|
Dec 18
2025
|
Anshul Maheshwari Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
18,542
-9.1%
|
$370,840
$20.15 P/Share
|
|
Dec 08
2025
|
Jeffrey W Dunn |
SELL
Open market or private sale
|
Indirect |
18,759
-14.56%
|
$356,421
$19.33 P/Share
|
|
Dec 08
2025
|
Jeffrey W Dunn |
SELL
Open market or private sale
|
Direct |
1,241
-10.75%
|
$23,579
$19.33 P/Share
|
|
Dec 08
2025
|
Jeffrey W Dunn |
BUY
Exercise of conversion of derivative security
|
Direct |
1,241
+9.7%
|
$4,964
$4.32 P/Share
|
|
Nov 25
2025
|
Anshul Maheshwari Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
100
-0.05%
|
$2,000
$20.0 P/Share
|
|
Nov 24
2025
|
Michael A Pisetsky SVP, Ops & Adm/Chief Legal Ofr |
SELL
Open market or private sale
|
Direct |
400
-0.16%
|
$8,000
$20.0 P/Share
|
|
Nov 21
2025
|
Anshul Maheshwari Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,200
-0.59%
|
$24,000
$20.01 P/Share
|
|
Nov 18
2025
|
Laura Francis Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
5,411
-1.52%
|
$91,987
$17.7 P/Share
|
|
Nov 17
2025
|
Anthony J Recupero President, Commercial Ops |
SELL
Open market or private sale
|
Direct |
3,833
-0.71%
|
$65,161
$17.44 P/Share
|
|
Nov 17
2025
|
Laura Francis Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,341
-0.68%
|
$192,797
$17.43 P/Share
|
|
Nov 17
2025
|
Anshul Maheshwari Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,460
-0.83%
|
$58,820
$17.43 P/Share
|
|
Nov 17
2025
|
Michael A Pisetsky SVP, Ops & Adm/Chief Legal Ofr |
SELL
Open market or private sale
|
Direct |
3,328
-0.65%
|
$56,576
$17.41 P/Share
|
|
Nov 11
2025
|
Anshul Maheshwari Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,601
-1.23%
|
$46,818
$18.33 P/Share
|
|
Nov 11
2025
|
Jeffrey W Dunn |
SELL
Open market or private sale
|
Direct |
80,000
-76.92%
|
$1,440,000
$18.95 P/Share
|
|
Nov 11
2025
|
Jeffrey W Dunn |
BUY
Exercise of conversion of derivative security
|
Direct |
80,000
+39.76%
|
$320,000
$4.32 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 484K shares |
|---|---|
| Exercise of conversion of derivative security | 103K shares |
| Open market or private sale | 461K shares |
|---|